Intelligence Profile
Clinical Applications
Current Evidence Base
Based on available literature, evidence for the clinical use of the combination therapy "Tesamorelin + Ipamorelin + MOTS-c" is extremely limited. A 2026 review in Sports Medicine examined peptide therapies for musculoskeletal injuries and athletic performance, but specific data on this three-compound combination was not identified in the search results.
Individual Component Applications
While the combination lacks robust clinical evidence, the individual peptides have been studied separately:
- Tesamorelin: FDA-approved for HIV-associated lipodystrophy and investigated for growth hormone deficiency
- Ipamorelin: Studied as a growth hormone secretagogue in research settings
- MOTS-c: Investigated in early research for metabolic applications
Evidence Limitations
The lack of dedicated clinical trials for this specific combination represents a significant evidence gap. Without controlled studies examining safety, efficacy, dosing, or drug interactions of these three peptides when used together, clinical applications remain theoretical rather than evidence-based.
Important Considerations
This combination therapy appears to be used in some clinical practices, potentially for goals related to:
- Body composition changes
- Athletic performance enhancement
- Anti-aging applications
However, these uses are not supported by robust clinical trial evidence for the combination specifically.
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a qualified healthcare provider before considering any peptide therapy, particularly unapproved combinations.